San Diego-based Viking Therapeutics marked alone as a serious competitor in the weight loss drug industry in February just after revealing promising information from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection As well as in March the company un